Baxalta Email Format

Biotechnology ResearchIllinois, United States201-500 Employees

Baxalta is a biotechnology research company based in Illinois, United States, focused on developing biologic therapies for immune-related and hematology conditions. The company launched CUVITRU, a subcutaneous immunoglobulin therapy for primary immunodeficiency, in the United States in 2016, and pursued multiple clinical trials around 2020. It also developed a PEGylated FVIII product, Adynovate, which was involved in patent litigation with Bayer, illustrating work in coagulation disorders.

According to the provided information, Baxalta was acquired by Shire in 2016, and later corporate changes included Takeda's acquisition of Shire and a 2026 spin-off by Baxter. The materials note that, after these corporate events, the Baxalta page would no longer be actively monitored and updates were redirected to Shire’s LinkedIn.

Sign up for free to view info

Company overview Employee directory